Elizabeth Munro, MD
Gynecologic Oncology · Portland, ORNPI 1508838897
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,675 of the $8,229 with a category attached, or 69.0%. Corcept Therapeutics accounts for 79.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $7,958, more than ten times the $28 reported in 2019.
Across 21 payments — averaging $391.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$7K
- Intuitive Surgical$2K
- Merck$75
- GSK$65
Across 5 payments — averaging $14,842 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$49K
- GSK$26K
What the payments were for
- Speaking & faculty fees$5,67569%
- Travel & lodging$97512%
- Food & beverage$4896%
- Education$1,09013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 8 | $6,553 |
| Intuitive Surgical | 9 | $1,537 |
| Merck | 3 | $75 |
| GSK | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,000
- Da Vinci Surgical System$273
How this compares
$8,229 in reported general payments places this provider in the 70th percentile of 25 gynecologic oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 23 | $485 |
| Dexamethasone | 28 | $316 |
| Oxycodone Hcl | 19 | $181 |
| Cephalexin | 13 | $144 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Portland
- Christopher DarusPortland$24K
- Tanja PejovicPortland$17K
- Gina WesthoffPortland$16K
- Kathryn McGoniglePortland$9K
- Amanda BrueglPortland$5K
- Amanda CompadrePortland$3K
- Erin SalinasPortland$3K
- Breana HillPortland$3K
- Jenna EmersonPortland$2K
- Jessica JouPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.